Financial Performance - The company's revenue for the first half of 2022 was RMB 460.1 million, a decrease of 31.4% compared to RMB 670.7 million in the same period of 2021[9]. - Gross profit for the first half of 2022 was RMB 274.5 million, down 39.8% from RMB 455.9 million in the first half of 2021, with a gross margin of 59.7%, a decline of 8.3 percentage points from 68.0%[9]. - The company recorded a total comprehensive loss of RMB 9.1 million in the first half of 2022, compared to a total comprehensive income of RMB 56.3 million in the same period of 2021[9]. - The loss attributable to owners of the company was RMB 6.6 million, with basic and diluted loss per share of RMB 0.1625, compared to a profit of RMB 26.4 million and earnings per share of RMB 0.6626 in the first half of 2021[9]. - Operating profit fell to RMB 12.2 million, a significant drop of 77.7% from RMB 53.6 million in the previous year[59]. - The company reported a net loss of RMB 9.1 million for the period, compared to a profit of RMB 56.3 million in the same period of 2021[59]. - The company reported a net cash inflow from operating activities of RMB 9,505 thousand for the six months ended June 30, 2022, compared to a net cash outflow of RMB 67,558 thousand for the same period in 2021[65]. - The company incurred total expenses of RMB 458,042,000 for the six months ended June 30, 2022, down from RMB 618,857,000 in the previous year, reflecting a reduction of approximately 26%[94]. Revenue Breakdown - Revenue from the "Three Teas" (Changrun Tea, Changqing Tea, and Xianxian Tea) was RMB 161.0 million, down 21.6% year-on-year[14]. - Weight loss product revenue was RMB 134.4 million, representing a significant decline of 52.9% compared to the same period last year[14]. - Revenue for the six months ended June 30, 2022, was RMB 460.1 million, a decline of 31.3% compared to RMB 670.7 million for the same period in 2021[59]. - Revenue from the e-commerce platform (Customer A) was approximately RMB 85,846,000, accounting for 18.7% of total revenue, down from 19.3% in the previous year[93]. Operational Challenges - The company faced a 53-day production halt at its Fangshan production base due to local pandemic control measures, impacting the shipment of core products[11]. - The domestic economy faced increased downward pressure due to the rapid spread of the Omicron variant and complex international conditions, with GDP growth slowing to 2.5% year-on-year in the first half of 2022[10]. - Retail sales of consumer goods in China decreased by 0.7% year-on-year in the first half of 2022, indicating weakened consumer confidence and suppressed consumption willingness[10]. Cost Management - Operating expenses totaled RMB 271.7 million in the first half of 2022, a reduction of 31.8% compared to RMB 398.5 million in the same period of 2021[9]. - Advertising expenses significantly decreased by RMB 50.7 million in the first half of 2022, attributed to reduced advertising activities[30]. - Total sales and marketing expenses fell to RMB 165.8 million, down from RMB 269.8 million in the previous year, representing a decrease of 38.5%[29]. - The company has optimized its organizational structure and reduced advertising expenses to manage operational costs effectively[14]. Research and Development - Research and development costs for the first half of 2022 were RMB 27.7 million, accounting for 6.0% of revenue, a decrease from RMB 54.2 million and 8.1% in the same period of 2021[32]. - The company is focusing on new product development in the areas of weight management and gastrointestinal health, with multiple new products in the pipeline[19]. Financial Position - As of June 30, 2022, the group’s cash and cash equivalents totaled RMB 382.2 million, down from RMB 425.0 million as of December 31, 2021[40]. - The group’s bank borrowings amounted to RMB 231.7 million as of June 30, 2022, with interest rates ranging from 3.70% to 6.80%[41]. - The group’s debt-to-asset ratio was 33.7% as of June 30, 2022, compared to 35.7% as of December 31, 2021[48]. - Non-current assets totaled RMB 925.4 million as of June 30, 2022, down from RMB 1,017.6 million at the end of 2021[61]. - Total assets decreased to RMB 1,540.6 million from RMB 1,642.1 million at the end of 2021[61]. Shareholder Information - The company proposed a rights issue to raise up to approximately HKD 142.6 million (approximately RMB 118.7 million) by issuing up to 81,510,390 shares at HKD 1.75 per share[157]. - The company has a total of 40,755,195 shares issued as of June 30, 2022[168]. - Mr. Zhao Yihong holds 21,050,219 shares, representing approximately 51.65% of the total issued shares[166]. - Ms. Gao Yan also holds 21,050,219 shares, equating to approximately 51.65% of the total issued shares[166]. Corporate Governance - The company has complied with the corporate governance code principles, except for the separation of roles between the Chairman and CEO as per code provision C.2.1[184][185]. - The audit committee consists of three independent non-executive directors and has reviewed the unaudited interim financial information for the six months ended June 30, 2022[186]. - The company did not purchase, sell, or redeem any of its listed securities during the six months ended June 30, 2022[189].

Financial Performance - Besunyen Holdings has sold over 5.585 billion bags of its three tea products, generating total sales exceeding RMB 7.494 billion as of December 31, 2021[3]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in 2021, representing a growth of 15% compared to the previous year[79]. - In 2021, the company's revenue decreased by 14.81% to RMB 1,101.15 million from RMB 1,292.71 million in 2020[41]. - The revenue from weight loss products fell by 37.18% to RMB 381.47 million, down from RMB 607.31 million in 2020[42]. - The revenue from other products and medicines increased by 87.81% to RMB 375.79 million, compared to RMB 200.14 million in 2020[42]. - The company's gross profit for 2021 was RMB 698.55 million, down from RMB 913.33 million in 2020[41]. - The net loss for the year was RMB 113.99 million, compared to a profit of RMB 130.86 million in 2020[41]. - The company reported a basic loss per share of RMB 9.13 in 2021, compared to earnings of RMB 2.85 per share in 2020[41]. Product Development and Market Strategy - The company has expanded its product offerings to include OTC weight loss products, specifically the Besunyen Orlistat capsules, which have received positive consumer feedback since their launch[3]. - The company aims to achieve a full industry chain layout covering pharmaceuticals, health foods, medical devices, and general foods[3]. - The company is actively developing new products tailored to current consumer demands to drive future revenue growth[25]. - The company has focused on a dual strategy of "one vertical and two horizontals" to enhance its competitive position in the health and wellness industry[24]. - The company plans to continue focusing on weight management and gastrointestinal health while launching innovative products[40]. - The company has expanded its sales channels to include short video platforms like Kuaishou and Douyin, aiming to reach a broader audience[25]. - The company launched 12 pharmaceutical products, 11 health foods, and 62 regular food items in 2021, expanding its product structure[30]. Acquisitions and Partnerships - Besunyen acquired Henan Xueyinghua Pharmaceutical Co., enhancing its capabilities in pharmaceutical R&D and production, thus establishing a comprehensive layout in the pharmaceutical sector[3]. - The acquisition of Xue Ying Hua was completed, leading to upgrades in production, quality, and safety management systems, with the production license obtained in November 2021[33]. - The company completed the acquisition of 100% equity in Xueyinghua for RMB 31.99 million on April 21, 2021[62]. - The new retail division established a strategic partnership with Kuaishou, enhancing short video and live streaming marketing, which improved customer value and sales performance[28]. Sales and Distribution - The company operates through 87 distributors and 142 sub-distributors, covering nearly 500,000 retail outlets across 31 provinces in China, facilitating robust offline sales[6]. - Online sales are conducted through 122 stores across 35 e-commerce platforms, allowing for rapid market entry of new products[6]. - The company's market share for its weight loss product, Biyuan Brand Changqing Tea, was approximately 22.74% in 2021, an increase of 0.36 percentage points year-on-year[25]. Financial Management and Expenses - Total sales and marketing expenses decreased from RMB 661.5 million in 2020 to RMB 521.8 million in 2021, representing 47.4% of revenue[46]. - Advertising expenses decreased by RMB 29.8 million, while employee benefits increased by RMB 18.7 million due to an increase in sales personnel[48]. - Administrative expenses rose by 29.76% from RMB 134.4 million in 2020 to RMB 174.4 million in 2021, mainly due to increased employee benefits[50]. - Research and development costs were RMB 93.1 million in 2021, slightly down from RMB 93.8 million in 2020, representing 8.5% of revenue[51]. Employee Management and Training - The company had 1,626 employees as of December 31, 2021, a decrease from 1,799 employees as of December 31, 2020[71]. - Employee costs, including director remuneration, amounted to RMB 291.9 million in 2021, up from RMB 226.9 million in 2020, reflecting a significant increase[71]. - The percentage of trained employees as of December 31, 2021, was 78.00% for junior staff, 15.50% for middle management, and 6.50% for senior management[142]. - Average training hours for employees were 120 hours for junior staff, 98 hours for middle management, and 66 hours for senior management[143]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes the importance of ESG initiatives, committing to reduce carbon emissions by 20% over the next five years[86]. - The company has implemented a top-down management approach for environmental, social, and governance (ESG) strategies, with the board responsible for assessing ESG risks and opportunities[90]. - Key ESG issues identified include air pollutant and greenhouse gas emissions management, supply chain management, business strategy and performance, product quality testing, and employee treatment[101]. - The company has committed to transparency in its ESG reporting, ensuring that all critical issues are reported in accordance with ESG guidelines[95]. Risk Management - The board is responsible for assessing the nature and extent of risks acceptable to achieve strategic objectives and ensuring effective risk management systems are in place[193]. - The company continues to optimize its risk management and internal control systems to adapt to the changing business environment and risks faced[194]. - The audit committee conducts regular assessments of major business risks and the effectiveness of the overall internal control system[197]. - The risk management process includes five steps: risk system organization, risk identification, risk assessment, risk handling, and reporting and control[199]. Community Engagement and Social Responsibility - The company donated over RMB 2.9 million to communities affected by flooding in Zhengzhou for disaster relief and reconstruction efforts[164]. - The company has established a professional customer service center and a consumer consultation hotline to manage complaints effectively[154]. - The company has not experienced any significant complaints or legal actions related to product quality and services during the reporting period[155].

Sales Performance - As of June 30, 2021, cumulative sales of the three tea products exceeded 5.48 billion bags[4] - The cumulative sales of 奥利司他 capsules surpassed 510 million units as of June 30, 2021[4] - The group's revenue for the first half of 2021 was RMB 670.7 million, an increase of 10.0% compared to RMB 609.8 million in the same period of 2020[15] - Revenue for the six months ended June 30, 2021, was RMB 670.7 million, an increase from RMB 609.8 million in the same period of 2020[89] - Revenue from other pharmaceuticals saw a significant increase of 392.0%, rising from RMB 16.3 million in 2020 to RMB 80.2 million in 2021, with its revenue share increasing from 2.7% to 12.0%[49] - Total revenue for the tea products segment was RMB 305,293,000 and for the weight loss and other pharmaceuticals segment was RMB 365,402,000, totaling RMB 670,695,000 for the first half of 2021[125] Market Position - The market share of Besunyen's 常菁茶 and 常潤茶 was 22.38% and 13.89% respectively, maintaining leading positions in the market[5] - The market share of Besunyen's 奥利司他 in the Alibaba e-commerce platform was 31.42%, ranking first in its category[5] Distribution and Sales Channels - The offline sales network covers nearly 400,000 OTC pharmacies and supermarkets across 31 provinces, regions, and municipalities in China[7] - The company operates 98 stores across 33 e-commerce platforms for the sale of its products[7] - The company has established a robust distribution network through 82 distributors and 158 sub-distributors[7] - The company is actively expanding its online pharmacy business and has established a team to enhance operations on platforms like JD.com and Tmall[19] - The company monitored channel inventory and sales data in real-time, focusing on inventory turnover rates and operational cost efficiency to ensure continuous growth[26] Financial Performance - The gross profit for the first half of 2021 was RMB 455.9 million, up 3.3% from RMB 441.3 million in the same period of 2020, with a gross margin of 68.0%, down 4.4 percentage points from 72.4% in 2020[15] - The total comprehensive income for the first half of 2021 was RMB 56.3 million, compared to RMB 47.3 million in the same period of 2020[15] - The company’s attributable comprehensive income for the first half of 2021 was RMB 26.4 million, significantly up from RMB 9.4 million in the same period of 2020, with basic and diluted earnings per share of RMB 1.66, compared to RMB 0.59 in 2020[15] - The company reported a net profit attributable to owners of the company of RMB 26.4 million for the six months ended June 30, 2021, up from RMB 9.4 million in the same period of 2020[89] - The company reported a total comprehensive income of RMB 26,429 thousand for the six months ended June 30, 2021, compared to RMB 47,292 thousand in the same period of 2020[95] Research and Development - The company is focusing on research and development in endocrine metabolism, ophthalmology, and antiviral drugs through its subsidiaries, enhancing its innovation capabilities[34] - The company aims to strengthen its research and development capabilities and actively introduce new products to enhance brand competitiveness in weight management and gastrointestinal health[41] - The company established an offline new product division and an online new product operation center to expand product offerings and meet diverse user needs[17] Marketing and Consumer Engagement - The company sponsored a food reality show that attracted over 1 billion views during the Spring Festival, increasing brand awareness and consumer engagement[26] - The company expanded its fan base through social marketing strategies, collaborating with Tencent and campus events, enhancing product offerings for young consumers[26] - The CRM team upgraded its marketing system to provide personalized health guidance and launched new products under the "Burn Card Queen" brand series, which received positive feedback from loyal users[23] Acquisitions and Investments - The company completed the acquisition of 100% equity in Xueyinghua for RMB 31.99 million on April 21, 2021, making it a wholly-owned subsidiary[74] - The company completed the acquisition of 100% equity in the pharmaceutical manufacturing company Xueyinghua for RMB 319.9 million on April 21, 2021[200] Operational Efficiency - Operating expenses for the first half of 2021 totaled RMB 399.5 million, a 4.4% increase from RMB 382.5 million in the same period of 2020[15] - Total administrative expenses increased to RMB 75.52 million, accounting for 11.3% of revenue, compared to 8.6% in the same period of 2020[55] - Total expenses for sales, marketing, administrative, and research and development amounted to RMB 619,897,000, an increase from RMB 552,541,000 in the previous year[130] Cash Flow and Liquidity - The group's cash outflow from operating activities was RMB 67.56 million, a decrease from a cash inflow of RMB 58.7 million in the same period of 2020[64] - Cash flow from operating activities showed a net outflow of RMB 67,558 thousand for the six months ended June 30, 2021, compared to an inflow of RMB 58,700 thousand in the same period of 2020[97] - The company's cash and cash equivalents decreased to RMB 287,256 thousand as of June 30, 2021, from RMB 543,822 thousand as of December 31, 2020, a decline of 47.3%[91] Assets and Liabilities - The company's debt-to-asset ratio as of June 30, 2021, was 32.1%, down from 34.7% on December 31, 2020[77] - Total liabilities decreased to RMB 574,648 thousand as of June 30, 2021, down from RMB 642,842 thousand as of December 31, 2020, a reduction of 10.6%[93] - The total net book value of property, plant, and equipment as of June 30, 2021, was RMB 369,571,000, an increase from RMB 322,278,000 at the end of 2020[150] Social Responsibility - The company donated RMB 150,000 to various charitable projects, demonstrating its commitment to social responsibility and sustainable development[35]

Sales and Market Performance - As of December 31, 2020, cumulative sales of the three tea products exceeded 5.35 billion bags, with total sales revenue surpassing RMB 7.15 billion[2]. - In 2020, the market share of Besunyen's Changqing Tea was 22.38%, and Changrun Tea was 13.89%, maintaining the leading position in the market[3]. - The combined market share of Besunyen's Orlistat products on Alibaba's e-commerce platforms reached 37%, ranking first in the sector[3]. - The market share of the Biyuan brand Changqing Tea in the weight loss product segment was 22.38% in 2020, a decrease of 3.84 percentage points year-on-year[23]. - The market share of the Biyuan brand Changrun Tea in the intestinal health product segment was 13.89% in 2020, a decrease of 0.96 percentage points year-on-year[23]. - In the weight loss drug segment, the combined market share of Biyuan brand Orlistat and Laili brand Orlistat was 37% in 2020, an increase of 2.66 percentage points year-on-year[23]. Financial Performance - The group's revenue for 2020 was RMB 1,292.7 million, an increase of 59.2% compared to RMB 812.2 million in 2019[21]. - Gross profit rose from RMB 584.5 million in 2019 to RMB 913.3 million in 2020, representing a 56.3% increase, while gross margin decreased from 72.0% to 70.7%[21]. - Total operating expenses for 2020 amounted to RMB 889.7 million, up 47.0% from RMB 605.1 million in 2019[21]. - The revenue from weight loss products rose by 87.1% to RMB 607.3 million in 2020, compared to RMB 324.5 million in 2019, increasing its share of total revenue from 40.0% to 47.0%[74]. - The total operating profit for the year was RMB 113.9 million, down from RMB 208.4 million in 2019[71]. - Other income for 2020 was RMB 26.7 million, including government subsidies of RMB 18.2 million, up from RMB 6.5 million in 2019[80]. Product Development and Innovation - The company has expanded its product offerings from weight loss herbal teas to include OTC weight loss medications, enhancing its market coverage[2]. - The company has focused on upgrading its brand and expanding its product line, including pharmaceuticals, health foods, medical devices, and ordinary foods[24]. - The company launched new products in major pharmacy chains, reshaping the product landscape in offline channels[36]. - The company is committed to deepening its research in weight management and gastrointestinal health while exploring new product categories and markets[52]. - New product development includes the launch of a health-focused beverage line, projected to contribute 200 million in revenue within the first year[126]. Marketing and Sales Strategies - The company has implemented a multi-channel sales model based on e-commerce platforms and adjusted its R&D and product strategies to enrich its product categories[20]. - The company has initiated innovative marketing models and expanded its sales channels from traditional methods to include internet marketing[24]. - The company increased its CRM team size and implemented a personalized sales model, leading to improved customer retention and product repurchase rates[32]. - The company launched a marketing campaign themed around public health during the pandemic featuring four key products, winning a gold award at the 9th Social Marketing Forum[47]. - The company has set a future outlook with a revenue target of 1.5 billion for the next fiscal year, indicating an expected growth of 25%[126]. Corporate Social Responsibility - The company has established a charity fund to support social welfare projects, donating RMB 450,000 for ecological construction and poverty alleviation initiatives[58]. - The company has received recognition as an outstanding corporate social responsibility enterprise at the 2020 China Corporate Social Responsibility Cloud Summit[59]. - The company actively participates in social responsibility initiatives, including poverty alleviation and environmental protection[153]. - The company has participated in various social responsibility initiatives, including poverty alleviation and ecological conservation projects[144]. Environmental Impact and Sustainability - The company emphasizes the importance of environmental protection and has implemented reforms such as "lean production," "clean production," and "green office" to enhance energy efficiency and reduce emissions[142]. - The greenhouse gas emissions in 2020 were 2,442 tons, a reduction of 770 tons compared to 2019, indicating the effectiveness of energy-saving and emission-reduction measures[165]. - The group’s industrial wastewater discharge in 2020 was 4,589 tons, with a wastewater generation rate of 1.31 tons per ton of finished product, an increase of 306 tons from 2019[169]. - The group implemented various measures to reduce waste emissions, including waste classification and lean production initiatives[171]. Workforce and Employee Management - The total employee cost for the year ended December 31, 2020, was RMB 226.9 million, an increase from RMB 191.7 million in 2019[119]. - The group had 1,437 employees as of December 31, 2020, compared to 1,187 employees in 2019, indicating a growth in workforce[119]. - The gender distribution of employees as of December 31, 2020, was 686 females (48%) and 751 males (52%)[194]. - The company has a strong focus on talent management, implementing a performance evaluation system that rewards high achievers and fosters employee potential[142]. Future Outlook and Strategic Initiatives - The company plans to strengthen e-commerce capabilities and enhance private traffic cultivation to create a closed-loop business model[62]. - The board of directors has approved a new strategic plan that includes diversifying product offerings and entering new markets, targeting a 30% increase in overall sales by 2025[126]. - The company is focusing on digital transformation initiatives, with an investment of 30 million aimed at improving online sales channels and customer engagement[126]. - A strategic acquisition of a local competitor is in progress, expected to enhance the company's distribution network and increase market penetration by 15%[126].

Financial Performance - The revenue for the first half of 2020 was RMB 609.8 million, an increase of 80.3% compared to RMB 338.2 million in the same period of 2019[10]. - Gross profit for the first half of 2020 was RMB 441.3 million, up 78.8% from RMB 246.8 million in the same period of 2019, with a gross margin of 72.4%[10]. - Operating expenses totaled RMB 382.5 million in the first half of 2020, a 51.2% increase from RMB 252.9 million in the same period of 2019[10]. - The operating profit for the first half of 2020 was RMB 60.1 million, compared to an operating loss of RMB 2.7 million in the same period of 2019 after excluding gains from the sale of subsidiaries[10]. - Total comprehensive income for the first half of 2020 was RMB 47.3 million, down from RMB 172.7 million in the same period of 2019[10]. - The basic and diluted earnings per share attributable to the company's owners for the first half of 2020 were RMB 0.59, a significant decrease from RMB 10.48 in the same period of 2019[11]. - Revenue for the six months ended June 30, 2020, was RMB 609,775 thousand, a significant increase of 80.3% compared to RMB 338,222 thousand in the same period of 2019[64]. - Gross profit for the same period was RMB 441,308 thousand, representing a gross margin of approximately 72.3%[64]. - Operating profit decreased to RMB 60,054 thousand from RMB 222,852 thousand, reflecting a decline of 73.0% year-on-year[64]. - Net profit for the period was RMB 47,292 thousand, down 72.6% from RMB 172,748 thousand in the previous year[64]. Market Position and Sales - The cumulative sales volume of the two main tea products exceeded 5.06 billion bags, with total sales revenue surpassing RMB 6.76 billion as of June 30, 2020[2]. - The market share of Besunyen's 常潤茶 was 14.85% and 常菁茶 was 26.22% as of 2019, maintaining a leading position in the market[3]. - The combined market share of Besunyen's and 来利's orlistat products was 38.3% in the Alibaba e-commerce platform, ranking first in the category[3]. - The revenue from weight loss products surged 180.3% to RMB 305.3 million, up from RMB 108.9 million in the first half of 2019[31]. - Revenue from the Bi Sheng Yuan brand Chang Run Tea rose by 9.4% to RMB 92.9 million, despite a 16.3% decrease in sales volume to 49.7 million tea bags[27]. - The average selling price of Chang Run Tea increased from RMB 1.43 per bag in the first half of 2019 to RMB 1.87 per bag in the first half of 2020[27]. E-commerce and Marketing Strategies - The company has established 49 online stores across 9 e-commerce platforms to enhance product distribution and market presence[5]. - The e-commerce team increased collaboration with major platforms, participating in promotional activities and utilizing live streaming to attract target customers, resulting in a growing user base[14]. - The company adopted a multi-channel sales model, integrating traditional and online channels to better reach consumers[16]. - The company plans to continue enhancing its e-commerce platform marketing efforts to drive future growth[31]. Research and Development - The company is focusing on R&D in the fields of weight management and gastrointestinal health, enhancing its competitive advantage through various forms of collaboration[19]. - The company is participating in key R&D projects in collaboration with renowned research institutions to modernize traditional Chinese medicine[20]. - The company has established a quality management team to oversee product quality and risk control, integrating resources from various departments[21]. - The company plans to accelerate the development of new products and expand its market presence, particularly targeting younger consumers[24]. Operational Efficiency - The company improved logistics management by monitoring inventory data directly from distributors, effectively controlling stock turnover and avoiding excess inventory[18]. - The sales team’s performance evaluation was upgraded to focus on net sales and achievement rates, fostering a strong marketing system[18]. - The company experienced a decrease in income tax expenses to RMB 11.2 million from RMB 34.8 million in the first half of 2019[40]. - The company reported a net cash inflow from operating activities of RMB 58.7 million, compared to a net cash outflow of RMB 40.1 million in the same period of 2019[44]. Corporate Governance and Management - The company has applied the principles of the Corporate Governance Code as set out in Appendix 14 of the Listing Rules, except for the provision A.2.1[197]. - The Chairman and CEO roles are held by the same individual, Zhao Yihong, who has 30 years of experience in the Chinese food and beverage industry[198]. - The Audit Committee consists of three independent non-executive directors, ensuring oversight of the company's financial reporting and internal controls[199].

Sales Performance - Besunyen Holdings has sold over 5.02 billion bags of its two main tea products, generating cumulative sales exceeding RMB 6.56 billion by the end of 2019[3]. - The company's revenue for 2019 was RMB 812.2 million, an increase of 114.6% compared to RMB 378.4 million in 2018[15]. - Gross profit rose from RMB 255.3 million in 2018 to RMB 584.5 million in 2019, representing an increase of 128.9%[15]. - The revenue from weight loss products surged by 384.3% to RMB 324.5 million, driven by increased promotion on e-commerce platforms[57]. - In 2019, the e-commerce sales increased by 185% compared to 2018, following a 75% growth from 2017 to 2018[28]. - During the Double 11 shopping festival, the company achieved sales of RMB 62.99 million, and over RMB 20 million during Double 12[31]. - Monthly sales on JD and Pinduoduo platforms exceeded RMB 10 million each in the second half of 2019[32]. Market Share - The market share for Besunyen's Changrun Tea is 14.85%, while Changqing Tea holds a market share of 26.22%, maintaining a leading position in the functional health tea market[4]. - In 2019, Besunyen's Orlistat products captured a combined market share of 34.34% on Alibaba's e-commerce platforms, ranking first in the segment[4]. - The market share of Bi Sheng Yuan's 常菁茶 in the weight loss product segment was 26.22% in 2019, a decrease of 6.97 percentage points year-on-year[16]. - The market share of Bi Sheng Yuan's 常潤茶 in the intestinal health product segment was 14.85% in 2019, an increase of 1.03 percentage points year-on-year[16]. - The combined market share of Bi Sheng Yuan's 奥利司他 and 来利牌奥利司他 in the e-commerce platform was 34.34% in 2019, ranking first[16]. Research and Development - The company has strengthened its R&D team and increased investment in new product development and introduction in 2019[14]. - The Orlistat production and R&D base in Guangdong has been recognized as a national intellectual property advantage enterprise[6]. - The company has successfully developed and launched new health food products, with 12 products currently under independent research and development[40]. - The company is actively participating in a key research and development program aimed at modernizing traditional Chinese medicine, focusing on powder and paste formulations[40]. - In 2019, the company completed the filing of 3 types of raw materials and conducted supplementary research on 4 drugs, with 11 new invention patents filed and 9 national invention patents granted[43]. Marketing Strategy - The company has shifted its marketing strategy towards innovative models, enhancing brand exposure and targeting younger consumers[17]. - The brand's marketing strategy included collaborations with media for targeted advertising, significantly increasing brand exposure among family demographics[23]. - The company initiated a brand upgrade campaign, focusing on content marketing and social media engagement to attract younger consumers[36]. - The company emphasizes brand rejuvenation, targeting younger consumers with products like meal replacement shakes and collagen jelly[116]. Financial Performance - The total operating expenses for 2019 were RMB 605.1 million, up 58.1% from RMB 382.8 million in 2018[15]. - The company reported a net profit of RMB 188.2 million for 2019, compared to a loss of RMB 93.5 million in 2018[56]. - Other income for 2019 included RMB 2.0 million in interest income and RMB 6.5 million in government subsidies[61]. - Administrative expenses decreased by 4.1% to RMB 107.8 million, primarily due to reduced depreciation related to property sales[66]. - Research and development costs increased by 101.7% from RMB 23.5 million in 2018 to RMB 47.4 million in 2019, representing 5.8% of total revenue[68]. Employee Development - As of December 31, 2019, the company had 1,187 employees, an increase from 1,121 employees in 2018[100]. - Employee costs for the year amounted to RMB 156.2 million, down from RMB 161.7 million in 2018, reflecting a decrease of approximately 3.1%[100]. - Continuous education and training programs are provided to employees to enhance their knowledge and skills[100]. - The company emphasizes the recruitment, motivation, and retention of suitable talent to enhance long-term development[100]. Environmental Responsibility - The company emphasizes the importance of building a resource-saving, environmentally friendly, and green enterprise as a key strategic goal for sustainable development[118]. - The company has made significant investments in upgrading equipment and optimizing management measures to reduce emissions of pollutants and greenhouse gases[129]. - The group implemented various environmental measures, resulting in a decrease in natural gas, industrial waste gas, sulfur dioxide, and nitrogen oxides emissions compared to 2018[132]. - The company encourages employees to participate in environmental protection activities, such as tree planting, to foster a culture of ecological responsibility[118]. Corporate Governance - The company has committed to corporate governance principles to protect shareholder interests and enhance corporate value and accountability[182]. - The board of directors consists of six members, including two executive directors and three independent non-executive directors, ensuring a diverse governance structure[185]. - The audit committee reviewed the consolidated financial statements for the year ended December 31, 2019, and discussed the accounting standards adopted by the group[192]. - The company has adopted a board diversity policy aimed at enhancing performance quality through diverse member selection based on various criteria including gender, age, cultural background, and professional experience[200].

Financial Performance - The company's revenue for the first half of 2019 was RMB 338.2 million, an increase of 101.7% compared to RMB 167.7 million in the same period of 2018[11]. - Gross profit for the first half of 2019 reached RMB 246.8 million, up 103.0% from RMB 121.6 million in the same period of 2018, with a gross margin of 73.0%[11]. - Operating expenses for the first half of 2019 totaled RMB 252.9 million, a 50.2% increase from RMB 168.4 million in the same period of 2018[11]. - The company recorded an operating profit of RMB 222.9 million for the first half of 2019, while the operating loss after excluding subsidiary sales was RMB 2.7 million, compared to an operating loss of RMB 35.8 million in the same period of 2018[11]. - Total comprehensive income for the first half of 2019 was RMB 172.7 million, compared to a total comprehensive loss of RMB 28.9 million in the same period of 2018[11]. - Basic and diluted earnings per share attributable to the owners of the company for the first half of 2019 were RMB 10.48, compared to a loss of RMB 1.64 per share in the same period of 2018[11]. Product and Market Development - The company’s core products maintained a leading market share, with the market share of Besunyen Regular Tea at 13.82% and Besunyen Slimming Tea at 33.19%[2]. - The company has extended its product line from health teas to weight loss medications, enhancing its market coverage[2]. - In the first half of 2019, the company launched several new products including jelly, collagen powder, and herbal teas on e-commerce platforms, focusing on weight management and gut health categories[12]. - The revenue from the weight loss drug "奧利司他" surged by 375.5% to RMB 108.9 million[38]. - The company has focused on optimizing its product structure, expanding from traditional herbal weight loss teas to OTC products, and launching new products targeting health-conscious young consumers[28]. Sales and Marketing Strategies - The company has established a nationwide sales network covering 31 provinces, autonomous regions, and municipalities, with 70 distributors and 246 dealers[2]. - The company increased brand exposure through strategic partnerships with radio stations, enhancing brand recognition and driving product sales[13]. - The company implemented targeted marketing through elevator media in nearly 70 cities, aiming to resonate emotionally with family consumers and improve sales in offline chain pharmacies[14]. - The company expanded its brand marketing by integrating into online dramas and variety shows, increasing brand awareness among younger audiences[17]. - The company organized a public advertising competition in collaboration with universities, enhancing brand reputation among young consumers[19]. Financial Position and Cash Flow - Cash and cash equivalents increased by 578.3% to RMB 383.9 million as of June 30, 2019, compared to RMB 56.6 million at the end of 2018[56]. - The group completed the sale of 100% equity in Beijing Changsheng and its wholly-owned subsidiary, Biyuan Property Company, for RMB 555.0 million, which significantly contributed to the increase in net profit for the first half of 2019[60]. - The group’s debt-to-asset ratio decreased to 21.6% as of June 30, 2019, down from 27.0% as of December 31, 2018[64]. - The company reported a net cash outflow from operating activities of RMB 40.1 million, significantly reduced from RMB 94.9 million in the previous year[55]. - The cash flow from financing activities showed a net outflow of RMB 77,534,000, a decrease from a net inflow of RMB 125,265,000 in the same period last year, indicating reduced reliance on external financing[88]. Employee and Operational Efficiency - Total employee costs for the six months ended June 30, 2019, amounted to RMB 84.4 million, an increase of 21.5% compared to RMB 69.2 million for the same period in 2018[66]. - The number of employees increased to 1,216 as of June 30, 2019, from 1,121 as of December 31, 2018[66]. - The company has made significant investments in employee training and development to enhance skills and collaboration[67]. - The company adjusted its sales team structure to enhance management efficiency and focus on pure sales growth, implementing a "3+1" management model[20]. Assets and Liabilities - Total assets as of June 30, 2019, amounted to RMB 1,558,495 thousand, an increase from RMB 1,436,768 thousand at the end of 2018[81]. - The company’s total liabilities decreased to RMB 336,804 thousand from RMB 387,863 thousand, a reduction of 13.2%[83]. - Trade receivables reached RMB 84,895,000, up 124.8% from RMB 37,844,000 as of December 31, 2018, with a net amount of RMB 84,150,000 after deducting bad debt provisions[164]. - The total lease liabilities amounted to RMB 28,038,000, with a weighted average incremental borrowing rate of 5.59%[191]. Tax and Regulatory Compliance - The effective tax rate for the period was approximately 17%, a decrease from 33% in 2018, primarily due to the net gain from the sale of subsidiaries offsetting previously recognized deductible temporary differences[143]. - The company has subsidiaries in China that qualify for a reduced corporate tax rate of 15% due to high-tech enterprise status, contributing to the overall tax strategy[142].

Sales Performance - The cumulative sales of the two main products, Besunyen Tea and Changqing Tea, exceeded 4.8 billion bags with total sales revenue surpassing RMB 6.2 billion as of the end of 2018[3] - In 2018, the company's revenue was RMB 378.4 million, a decrease of 22.4% compared to RMB 487.8 million in 2017[64] - Gross profit fell from RMB 375.1 million in 2017 to RMB 255.3 million in 2018, a decline of 31.9%, with gross margin decreasing from 76.9% to 67.5%[64] - The sales volume of Bi Sheng Yuan's Chang Run Tea dropped from 151.7 million bags in 2017 to 86.3 million bags in 2018, a decline of 43.8%[98] - The revenue from weight loss products increased by 19.0% to RMB 67.0 million in 2018[98] Market Position - The market share of Changrun Tea is 13.82% and Changqing Tea is 33.19%, maintaining the leading position in the market[4] - The market share of Biyuan brand Changqing Tea in the weight loss product segment was 33.19% in 2018, an increase of 1.33 percentage points year-on-year[65] - Biyuan brand Changrun Tea held a market share of 13.82% in the intestinal health product segment in 2018, a decrease of 0.73 percentage points year-on-year[65] Distribution and Sales Network - The sales team covers all 31 provinces, autonomous regions, and municipalities in China, serving nearly 100,000 OTC retail stores[5] - The company has 63 distributors and 232 wholesalers, enhancing its national sales network[5] - The company aims to leverage its existing distribution channels for faster market entry of new products, maintaining its industry-leading position[5] Product Development and R&D - The company has extended its product line into the weight loss pharmaceutical market through partnerships and acquisitions, including the acquisition of Zhongshan Wanhua Pharmaceutical Co., Ltd.[3] - The company focuses on natural herbal ingredients for its products, providing safe and effective health solutions for weight management[4] - The company has a strong commitment to research and development in functional health teas and pharmaceuticals, enhancing its competitive edge in the market[3] - In 2018, the company registered six new eye drop products and submitted 21 invention patent applications, reflecting its commitment to R&D and product development[87] - The company aims to expand its product line and enhance R&D capabilities to improve its competitive position in the health industry[61] Marketing Strategies - The company has focused on innovation in marketing strategies and explored e-commerce channels to enhance brand promotion[66] - The collaboration with the "Sakura Girls" live streaming event resulted in over 30 million views and 4.68 billion total brand exposures, significantly boosting brand awareness among younger demographics[73] - The "Little Blue Box" marketing campaign on platforms like Douyin and Weibo generated over 300 million views and 50,000 discussions, effectively engaging the youth market[74] - The company signed contracts for six new product placements in popular TV dramas, aiming to enhance brand visibility and appeal to younger audiences[77] - The brand's new image campaign emphasized youthfulness and health, aligning with its marketing transformation goals[71] Financial Performance - The company recorded a total comprehensive loss of RMB 93.5 million in 2018, compared to a total comprehensive income of RMB 5.3 million in 2017[64] - The company's net loss for the year was RMB 93.472 million, compared to a profit of RMB 5.281 million in 2017, with a loss attributable to owners of the company amounting to RMB 95.299 million[94] - The total operating expenses for 2018 were RMB 382.8 million, down 6.0% from RMB 407.4 million in 2017[64] - The company's administrative expenses rose by 5.1% to RMB 112.4 million, accounting for 29.7% of total revenue[107] Corporate Social Responsibility - The company has established a charity fund to support social welfare activities, enhancing its corporate social responsibility initiatives[88] - The company received the "2018 Outstanding Corporate Social Responsibility Award" for its active participation in social welfare projects[89] - The group has a commitment to corporate social responsibility, aligning its development with national goals and promoting a healthy lifestyle[165] Environmental Impact - The company reported industrial waste gas emissions of 1,627,668 cubic meters in 2018, an increase from 1,336,430 cubic meters in 2017[180] - The company generated 4,533 tons of industrial wastewater in 2018, with a per ton production wastewater generation of 4 tons, which increased by 3,582 tons compared to 2017[187] - The company has implemented comprehensive measures for wastewater treatment, ensuring compliance with the Water Pollution Prevention Law[183] - The company has committed to sustainable development by promoting "clean production" and actively engaging employees in environmental protection activities[177] Employee Management - The company maintained a workforce of 1,121 employees as of December 31, 2018, an increase from 1,020 employees in 2017[141] - The group has implemented a human resources management philosophy that respects talent and motivates employees through scientific assessment policies[167] Quality Management - The production facilities comply with national GMP standards and have received ISO9001, ISO22000, and HACCP certifications[4] - The group emphasizes strict quality management, considering product safety as the top priority for corporate life[167] - The company has established a packaging material procurement system to ensure compliance with national food safety standards[199]